Table 2 Comparative analysis of VKH patients baseline demographic data and clinical features of VKH eyes with and without glaucoma

Female gender

68 (85.0)

20 (100.0)

0.327

Age (years)^a

35 (26.7–45.7)

37 (29–54)

0.304

 Poliosis

2 (5.0)

2 (20.0)

0.049

 Vitiligo

4 (10.0)

3 (30.0)

0.021

 Flu-like

14 (35.0)

4 (40.0)

0.600

 Headache

30 (75.0)

8 (80.0)

0.640

 Tinnitus

25 (62.5)

5 (50.0)

0.307

 Uveitic

62 (77.5)

7 (35.0)

< 0.001

 Chronic-recurrent

14 (17.5)

13 (65.0)

< 0.001

 Convalescent

4 (5.0)

0 (0)

< 0.001

 Open

64 (80.0)

5 (25.0)

< 0.001 

 Closed

16 (20.0)

15 (75.0)

< 0.001

BCVA (LogMAR)^a

0.2 (0–0.6)

0.55 (0.22–2.3)

0.003

 Sunset glow fundus

50 (62.5)

16 (88.9)^c

0.031

 Dalen-Fuchs nodules

58 (60)

18 (100)^c

0.001

 Serous retinal detachment

2 (2.5)

1 (5.6)^c

0.460

 Peripapillary atrophy

39 (37.5)

14 (77.8)^c

0.002

 Papillitis

2 (2.5)

0 (0)

< 0.001

C/D ratio (n = 35)^ad

0.4 (0.3–0.4)

0.8 (0.55–0.9)

< 0.001

Recurrence (yes)

44 (55.0)

15 (75.0)

0.130

Time to achieve inflammatory control (months)^a

2 (1–3)

3 (2–3)

0.026

Time to first recurrence (months)^a

5 (2–8)

18 (8–48)

< 0.001

Exposure topical steroids (months)^a

8.5 (2.2–24)

25 (14–54)

0.008

Exposure oral prednisone (months)^a

11.5 (7–26.7)

62 (39–104)

< 0.001